Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

ABBOTT LABORATORIES Director's Dealing 2017

Feb 22, 2017

29777_dirs_2017-02-22_36a84fa8-9b07-4bcb-bfdc-a4dd061fa5e8.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ABBOTT LABORATORIES (ABT)
CIK: 0000001800
Period of Report: 2017-02-17

Reporting Person: Mason Heather L (Executive Vice President)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2017-02-17 Common shares without par value A 5630 Acquired 70119 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2017-02-17 Option (right to buy) $44.40 A 38940 Acquired 2027-02-16 Common shares (38940) Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common shares without par value 70000 Indirect

Footnotes

F1: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes.

F2: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 12,980 on 02/17/2018, 12,980 on 02/17/2019, and 12,980 on 02/17/2020.